An ascending multiple-dose study of the safety, pharmacokinetics, and pharmacodynamics of PAZ-417 administered orally to elderly subjects

Trial Profile

An ascending multiple-dose study of the safety, pharmacokinetics, and pharmacodynamics of PAZ-417 administered orally to elderly subjects

Discontinued
Phase of Trial: Phase I

Latest Information Update: 19 Jan 2010

At a glance

  • Drugs Aleplasinin (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors Wyeth
  • Most Recent Events

    • 05 Aug 2009 Planned end date changed from 1 Sep 2008 to 1 Dec 2008 as reported by ClinicalTrials.gov.
    • 22 Jul 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 15 Jul 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top